abstract |
The present invention is directed to an improved pharmaceutical formulation comprising dehydroepiandrosterone (DHEA) concentrated in selected polymorphic forms for use in the therapeutic field. In one embodiment, the formulation comprises at least 85% solid DHEA and one or more pharmaceutical excipients present as one polymorph selected from Form I polymorph or Form II polymorph. The present invention also relates to methods of making and using such compositions. |